Welcome to our dedicated page for Swedish Orphan Biovitrum AB news (Ticker: SWOBY), a resource for investors and traders seeking the latest updates and insights on Swedish Orphan Biovitrum AB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Swedish Orphan Biovitrum AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Swedish Orphan Biovitrum AB's position in the market.
Swedish Orphan Biovitrum (BIOVF) announced that its Board of Directors has authorized the repurchase of all issued class C shares following the Annual General Meeting resolution from May 8, 2025. The repurchase is specifically aimed at fulfilling commitments under the company's long-term incentive programmes.
The repurchase will be conducted at 100% of the quotient value (approximately SEK 0.55 per share) and will occur between July 16 and November 7, 2025. Following the repurchase and conversion of C shares to common shares, Sobi's total holdings of own common shares will increase from 11,377,680 to 12,790,468. The company reported revenue of SEK 26 billion in 2024 and employs approximately 1,900 people globally.
FAQ
What is the current stock price of Swedish Orphan Biovitrum AB (SWOBY)?
